Patent directory · USPTO A61K / A61P
Patents matching “CRISPR THERAPEUTICS AG”
77 pharma patents match "CRISPR THERAPEUTICS AG" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 77 pharmaceutical patents matching "CRISPR THERAPEUTICS AG" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12427170
Universal donor cells
granted -
US 12344655
Gene-edited natural killer cells
granted -
US 12344656
Genetically engineered T cells having improved persistence in culture
granted -
US 12304968
T-cells expressing anti-LIV1 chimeric antigen receptor
granted -
US 12263227
Optimized mRNA encoding CAS9 for use in LNPs
granted -
US 12247201
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
granted -
US 12241087
Compositions and methods for differentiating stem cells into NK cells
granted -
US 12227763
Methods and compositions for treating cancer
granted -
US 12215316
Materials and methods for treatment of usher syndrome type 2A
granted -
US 12215320
Compositions and methods for gene editing by targeting transferrin
granted -
US 12186406
Materials and methods for treatment of hereditary haemochromatosis
granted -
US 12188060
Messenger RNA encoding Cas9 for use in genome-editing systems
granted -
US 12122998
Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
granted -
US 12037616
Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
granted -
US 12016932
Gene editing for hemophilia A with improved factor VIII expression
granted -
US 11958908
Compositions and methods for the depletion of CD117+ cells
granted -
US 11926676
Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such
granted -
US 11866727
Materials and methods for treatment of glycogen storage disease type 1A
granted -
US 11857574
Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
granted -
US 11851653
Materials and methods for treatment of alpha-1 antitrypsin deficiency
granted -
US 11833225
Methods and compositions for efficient gene deletion
granted -
US 11827877
Compositions and methods for genomic editing by insertion of donor polynucleotides
granted -
US 11679131
Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
granted -
US 11679130
Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
granted